Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal casts long shadow R&D

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that questions remain over past data integrity, despite new leadership being keen to move on from the scandal.